Business Context and Reporting Period
This Form 6-K filing by Alterity Therapeutics Limited (formerly Prana Biotechnology Limited) covers the month of April 2019, with the report dated April 11, 2019. The filing serves as a Final Director's Interest Notice submitted to the Australian Securities Exchange (ASX) and incorporated by reference into U.S. registration statements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding director interests rather than a financial performance report.
Material Changes
The primary material change disclosed is the cessation of Dr. Ira Shoulson's role as a director of the company, effective April 8, 2019. The filing details his remaining relevant interests in the company's securities at the time of departure.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly adheres to the requirements of ASX Listing Rule 3.19A.3 and Section 205G of the Corporations Act regarding director disclosures.
Investor Verification Points
- Director Departure: Verify the effective date of Dr. Ira Shoulson's resignation (April 8, 2019) and any associated corporate governance changes.
- Option Holdings: Confirm that Dr. Shoulson retains 1,250,000 unlisted options exercisable at A$0.11, with an expiry date of December 14, 2022.
- Contractual Interests: Note that the filing explicitly states there are no director interests in contracts (Part 3 is Nil).
- Registered Status: Verify that the disclosed options are held as registered securities by the director (Part 1), with no unregistered interests (Part 2 is Nil).